The Impact of COVID-19
on Clinical Research



What is the

Heart Failure Collaboratory (HFC)?

Efficiency of clinical trials and evidence generation in heart failure and foster development of therapies by creating a collaborative environment in which FDA, government agencies including NIH and CMS, and the heart failure community can interact to optimize innovation and advancement of new therapeutic products. HFC has established five working groups to tackle individual issues in clinical trials and fostering the development of effective heart failure therapies.

The Heart Failure Collaboratory is a public-private partnership with the FDA and the consortium to help foster the development of new products for heart failure.

Follow us on Twitter

Dr Califf moves through committee for FDA Chief with comfortable majority, ready for full Senate vote , let your Senators know ⁦@HeartBobH⁩ ⁦@texhern⁩ ⁦@NancyatHeart⁩ ...

HAPPENING TODAY! U.S. Senate to vote on the nomination of Dr. Robert Califf (@califf001) as @US_FDA Commissioner! @coconnormd @mfiuzat @mpsotka @DrNasrien @HeartBobH @mvaduganathan



Happening this week! Senate Committee Vote on ⁦@califf001⁩ for FDA Commissioner - Wednesday 🤞⁩ ⁦@hfcollaboratory⁩ ...

Load More...

Recent Publications

Access our latest publications, downloads and meeting notes.
Cost and Value in Contemporary Heart Failure Clinical Guidance Documents
In an era of rising health care costs and expanding therapeutic options, there is an increasing need for formal consideration of cost and value in the development of HF CGDs. This study sought to evaluate the frequency and nature of cost/value statements in contemporary heart failure (HF) clinical guidance documents (CGDs).
Use of Actigraphy (Wearable Digital Sensors to Monitor Activity) in Heart Failure Randomized Clinical Trials: A Scoping Review
Actigraphy-based measurements of physiologic parameters may enable design of patient-centric heart failure (HF) clinical trials. Recently, the Heart Failure Collaboratory focused on recommendations for meaningful change and use of actigraphy as an end point in HF clinical trials.
Promoting Diversity in Clinical Trial Leadership: A Call to Action
As a community of investigators, we have struggled to improve the recruitment of representative populations into heart failure (HF) trials.